Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Additionally we are shipping beta-Site APP-Cleaving Enzyme 1 Kits (70) and beta-Site APP-Cleaving Enzyme 1 Proteins (33) and many more products for this protein.
Showing 10 out of 228 products:
Human Polyclonal BACE Primary Antibody for IF (p), IHC (p) - ABIN725705
Tian, Guo, Wu, Ma, Zhao: Minocycline Alleviates Sevoflurane-Induced Cognitive Impairment in Aged Rats. in Cellular and molecular neurobiology 2015
Show all 5 Pubmed References
Human Monoclonal BACE Primary Antibody for CyTOF, FACS - ABIN4900525
Cheng, He, Lee, Yao, Li, Shen: High activities of BACE1 in brains with mild cognitive impairment. in The American journal of pathology 2013
Show all 3 Pubmed References
Human Polyclonal BACE Primary Antibody for IHC (p), WB - ABIN392201
Xie, Guo: PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. in The Journal of biological chemistry 2005
Show all 5 Pubmed References
Human Polyclonal BACE Primary Antibody for WB - ABIN550289
Vassar, Bennett, Babu-Khan, Kahn, Mendiaz, Denis, Teplow, Ross, Amarante, Loeloff, Luo, Fisher, Fuller, Edenson, Lile, Jarosinski, Biere, Curran, Burgess, Louis, Collins, Treanor, Rogers, Citron: Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. in Science (New York, N.Y.) 1999
Show all 3 Pubmed References
Their anti-BACE1 and antimicrobial activity.
Structural arrangement of BACE1-TM trimers and a mechanism for copper ion conduction that might also apply to other proteins involved in metal ion transport.
Potentials for beneficial or consequential effects resulting from pharmacologic inhibition of BACE1 are reviewed in context of ongoing clinical trials testing the effect of BACE1 candidate inhibitor drugs in Alzheimer's disease populations.
Measured plasma levels of beta-secretase 1 (BACE1) long non-coding RNA(LncRNA) in Alzheimer disease (AD) patients and healthy controls; found plasma BACE1 LncRNA to be a specific biomarker for AD.
Amyloid beta oligomers modulate BACE1 through an XBP-1 (show XBP1 Antibodies)-dependent pathway involving HRD1 (show SYVN1 Antibodies).
Polymethoxyflavones isolated from citrus peels might be considered as promising BACE1 inhibitory agents that could lower Abeta (show APP Antibodies) production in Alzheimer disease.
In BACE1 transgenic (Tg) mice, axonal regeneration was reduced when compared with wilde-type (WT) littermates at 3 and 10 days post crush. Study observed a decreased percentage of innervated neuromuscular junctions at 15 days post crush; and a functional recovery delay in the transgenic mice as it took 8 weeks for the compound muscle action potential amplitudes of Tg mice to begin to reach similar values comparable to WT.
Our study demonstrated there may exist an association between BACE1 rs535860 polymorphism and focal seizures in Chinese Han males.
This study shown that the protein expression of BACE1 is downregulated by chronic treatment with donepezil. This effect may be interpreted as evidence of disease modification.
Endosome-to-TGN (show TG Antibodies) trafficking of BACE1 is regulated by Par3 (show F2RL2 Antibodies) and aPKC. This is a mechanism in pathogenesis of Alzheimer disease.
BACE1 deficiency develops abnormal clusters of immature neurons, forming doublecortin (show DCX Antibodies)-positive neuroblasts, in the developing dentate gyrus, mainly in the subpial zone.
Increased TNFR1 (show TNFRSF1A Antibodies) expression and signaling in injured peripheral nerves of mice with reduced BACE1 activity
We aimed to explore the potential therapeutic effect of PGC-1alpha by generating a lentiviral vector to express human PGC-1alpha and target it by stereotaxic delivery to hippocampus and cortex of APP23 transgenic mice . Four months after hPGC-1alpha injection, mice showed improved spatial and recognition memory concomitant with a significant reduction in Abeta (show APP Antibodies) deposition, associated with a decrease in BACE1 expression
that BACE1 deficiency enhances proliferation of Schwann cell due to the elevated Jag1 (show JAG1 Antibodies)/Delta1-Notch (show NOTCH1 Antibodies) signaling
the synaptic localization of APP (show APP Antibodies), ADAM10 (show ADAM10 Antibodies), and BACE1 in the mouse cerebral cortex, was examined.
study demonstrates that SEZ6 and SEZ6L (show SEZ6L Antibodies) are physiological BACE1 substrates in the murine brain and suggests that sSEZ6 and sSEZ6L levels in CSF (show CSF2 Antibodies) are suitable markers to monitor BACE1 inhibition in mice
Chronic variable stress led to increased Bace1 expression in the hippocampus of young adult mice and the hippocampus, prefrontal cortex and amygdala of aged mice. The increased expression of Bace1 was associated with decreased methylation of several CpGs in the Bace1 promoter region.
Results indicate that SNX4 (show SNX4 Antibodies)-mediated regulation of the steady-state levels and trafficking of BACE1, as well as the subsequent increase in BACE1-mediated cleavage, may be relevant to Alzheimer's disease progression.
In conclusion, glucocorticoid couples mGR (show GRHL1 Antibodies) with Galphas (show GNAS Antibodies) and triggers cAMP-PKA-CREB (show CREB1 Antibodies) axis dependent on the lipid raft to stimulate BACE1 upregulation and Abeta (show APP Antibodies) generation.SIGNIFICANCE STATEMENT Patients with Alzheimer's disease (AD) have been growing sharply and stress is considered as the major environment factor of AD.
bace1 mutants display hypomyelination in the peripheral nervous system and supernumerary neuromasts while in bace2 (show BACE2 Antibodies) mutants the shape and migration of melanocytes is affected.
Cerebral deposition of amyloid beta peptide is an early and critical feature of Alzheimer's disease. Amyloid beta peptide is generated by proteolytic cleavage of amyloid precursor protein (APP) by two proteases, one of which is the protein encoded by this gene. The encoded protein, a member of the peptidase A1 protein family, is a type I integral membrane glycoprotein and aspartic protease that is found mainly in the Golgi. Multiple transcript variants encoding different isoforms have been described for this gene.
, asp 2
, aspartyl protease 2
, beta-secretase 1
, beta-secretase 1 precursor variant 1
, beta-site APP cleaving enzyme 1
, beta-site amyloid beta A4 precursor protein-cleaving enzyme
, membrane-associated aspartic protease 2
, transmembrane aspartic proteinase Asp2
, beta-site amyloid precursor protein cleaving enzyme 1
, beta-site APP cleaving enzyme
, beta secretase 1
, beta-secretase 1 isoform A preproprotein
, beta-secretase 1 isoform B preproprotein
, beta-secretase 1 isoform C preproprotein
, beta-site APP-cleaving enzyme 1
, beta-secretase 1-like